MADISON, N.J. (Legal Newsline) – Quest Diagnostics announced Monday that it and Myriad Genetics Inc. have reached an agreement that will end litigation over patents on two genes associated with hereditary breast and ovarian cancer.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.
